Arsenic degrades PML or PML-RARα through a SUMO-triggered RNF4/ ubiquitin-mediated pathway

Nature Cell Biology

Volumn 10, Issue 5, 2008, Pages 547-555

  Lallemand Breitenbach, Valérie ^a   Jeanne, Marion ^a   Benhenda, Shirine ^a   Nasr, Rihab ^a   Lei, Ming ^a   Peres, Laurent ^a   Zhou, Jun ^a,b   Raught, Brian ^c   de Thé, Hugues ^a,b,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; HYBRID PROTEIN; LYSINE; MUTANT PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; RETINOIC ACID RECEPTOR ALPHA; RING FINGER PROTEIN; RING FINGER PROTEIN 4; SUMO PROTEIN; UBIQUITIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS INCLUSION BODY; CELL TRANSFORMATION; CHO CELL; CONTROLLED STUDY; DRUG MECHANISM; GENETIC TRANSDUCTION; HELA CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION;

ANIMALS; ARSENIC; CELL DIFFERENTIATION; CELL LINE; HUMANS; MICE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; POLYUBIQUITIN; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; SUMO-1 PROTEIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 43049096803     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1717     Document Type: Article

References (34)

1. Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de Thé, H. How acute promyelocytic leukaemia revived arsenic. Nature Rev. Cancer 2 705-713. (2002).
2. Zhu, J. et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 3978-3983. (1997).
3. Muller, S., Matunis, M. J. & Dejean, A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17, 61-70 (1998).
4. Shao, W. et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARa protein in acute promyelocytic leukemia cells. J. Natl Cancer Inst. 96, 124-133 (1998).
5. Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) SUMOylation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor a Degradation. J. Exp. Med. 193, 1361-1372. (2001).
6. Chen, G. Q. et al. Use of arsenic trioxide (As2O3). in,the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects in APL cells. Blood 89, 3345-3353 (1997).
7. Davison, K., Mann, K. K., Waxman, S. & Miller, W. H., Jr JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103, 3496-3502 (2004)
8. Miller, W. H., Jr., Schipper, H. M., Lee, J. S., Singer, J. & Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893-3903 (2002).
9. Boddy, M. N., Howe, K., Etkin, L. D., Solomon, E. & Freemont, P. S. PIC1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13, 971-982 (1996).
10. Saitoh, H. & Hinchey, J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252-6258 (2000).
11. Sun, H., Leverson, J. D. & Hunter, T. Conserved function of RNF4 family proteins in eukaryotes: Targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26, 4102-4112 (2007).
12. Prudden, J. et al. SUMO-targeted ubiquitin ligases in genome stability. EMBO J. 26, 4089-4101 (2007).
13. Uzunova, K. et al. Ubiquitin-dependent proteolytic control of SUMO conjugates. J. Biol. Chem. 282, 34167-34175 (2007).
14. Xie, Y. et al. The yeast Hex3.Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J. Biol. Chem. 282 34176-34184 (2007).
15. Salomoni, P. & Pandolfi, P. P. The role of PML in tumor suppression. Cell 108, 165-170. (2002).
16. Kamitani, T. et al. Identification of three major sentrinization sites in PML. J. Biol. Chem. 41, 26675-26682 (1998).
17. Shen, T. H., Lin, H. K., Scaglioni, P. P., Yung, T. M. & Pandolfi, P. P. The mechanisms of PML-nuclear body formation. Mol. Cell 24, 331-339 (2006).
18. Anton, L. C. et al. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell Biol. 146, 113-124 (1999).
19. Fabunmi, R. P., Wigley, W. C., Thomas, P. J. & DeMartino, G. N. Interferon y regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. J. Cell Sci. 114, 29-36 (2001).
20. Ju, D. & Xie, Y. Identification of the preferential ubiquitination site and ubiquitin-dependent degradation signal of Rpn4. J. Biol. Chem. 281, 10657-10662 (2006).
21. Duprez, E. et al. SUMO-I modification of the acute promyelocytic leukaemia protein PML: Implications for nuclear localisation. J. Cell Sci. 112, 381-393 (1999).
22. Tatham, M. H. et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276, 35368-35374 (2001).
23. Hakli, M., Lorick, K. L., Weissman, A. M., Janne, O. A. & Palvimo, J. J. Transcriptional co-regulator SNURF (RNF4) possesses ubiquitin E3 ligase activity. FEBS Lett. 560, 56-62 (2004).
24. Hecker, C. M., Rabiller, M., Haglund, K., Bayer, P. & Dikic, I. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 281, 16117-16127 (2006).
25. Hakli, M., Karvonen, U., Janne, O. A. & Palvimo, J. J. SUMO-1 promotes association of SNURF (RNF4) with PML nuclear bodies. Exp. Cell Res. 304, 224-233 (2005).
26. Zhu, J. et al. A sumoylation site in PML/RAR α is essential for leukemic transformation. Cancer Cell 7, 143-153 (2005).
27. Cheng, J., Kang, X., Zhang, S. & Yeh, E. T. SUMO-specific protease 1 is essential for stabilization of HIF1β during hypoxia. Cell 131 584-595 (2007).
28. Fu, C. et al. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24, 5401-5413 (2005).
29. Knipscheer, P., van Dijk, W. J., Olsen, J. V., Mann, M. & Sixma, T. K. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. EMBO J. 26, 2797-2807 (2007).
30. Matic, I. et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol. Cell Proteomics 7, 132-144 (6 April 2008).
31. Tatham, M. H. et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nature Cell Biol. advance online publication doi:10.1038/ncb1716 (2008).
32. Lafarga, M. et al. Clastosome: A subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin and protein substrates of proteasome. Mol. Biol. Cell 13, 2771-2782 (2002).
33. Boutell, C., Orr, A. & Everett, R. D. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J. Virol. 77, 8686-8694 (2003).
34. Pedrioli, P. G. et al. Automated identification of SUMOylation sites using mass spectrometry and SUMmOn pattern recognition software. Nature Methods 3, 533-539 (2006).